Loading
A phase 1/2 trial of VRT106 in glioma & glioblastoma, run by Guangzhou Virotech Pharmaceutical Co., Ltd., now recruiting.
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma is a phase 1/2 interventional study registered as NCT07093814 by Guangzhou Virotech Pharmaceutical Co., Ltd., with 42 participants planned, started 2025-09-02 and due to reach its primary completion in 2028-12-31. Interventions recorded: VRT106.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Guangzhou Virotech Pharmaceutical, Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/